Cytyc scores extension to Scottish ThinPrep contract:
This article was originally published in Clinica
Cytyc UK, the Crawley, West Sussex division of the US developer of liquid-based cytology systems, has secured a five-year extension to its exclusive contract with Scotland's national health service. Under the agreement, Cytyc will supply its ThinPrep pap test - used for screening cervical cancer - to all 11 Scottish laboratories involved in the region's cervical screening programme. The deal is expected to cover around 2.2 million ThinPrep tests being sold during the term of the contract. Aside from Scotland, Cytyc also has on-going supply contracts with the London, South West and South East regions of the UK NHS.
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.